Comparison · NCT01060072-4a4cd80d
Loteprednol Etabonate vs Vehicle: Grade 0 Pain
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Loteprednol Etabonate vs Vehicle: Grade 0 Pain. Trial comparisons, record NCT01060072-4a4cd80d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01060072-4a4cd80d
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.757 | 0.694 | 0.811 | wilson | |
| Risk in group 2 | 0.458 | 0.39 | 0.527 | wilson | |
| Risk difference, group 1 minus group 2 | 0.3 | 0.206 | 0.386 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.65 | 1.4 | 1.96 | log | |
| Odds ratio, group 1 over group 2 | 3.7 | 2.42 | 5.64 | log | |
| Number needed to treat, for one more participant with the outcome on Loteprednol Etabonate than on Vehicle | 3.34 | 2.59 | 4.85 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: vehicle.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Loteprednol Etabonate | Loteprednol etabonate 0.5% ophthalmic suspension | 156 | 206 | OG000 |
| Group 2 | Vehicle | Vehicle of loteprednol etabonate ophthalmic suspension. | 92 | 201 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Grade 0 Pain
- Description
- Participants with no pain, graded on a 0-5 scale, 0=no pain and 5=severe pain
- Time frame
- Visit 5 (Postoperative day 8)
- Population
- Intention to treat (ITT) population
Source ClinicalTrials.gov
Trial
- Title
- Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery
- NCT number
- NCT01060072
- Phases
- PHASE3
- Conditions
- Inflammation, Pain
- Interventions
- Loteprednol etabonate, Vehicle of Loteprednol Etabonate
- Lead sponsor
- Bausch & Lomb Incorporated
- Results first posted
- 2012-01-13
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT01060072?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT01060072-4a4cd80d